We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Biosensor Platform Monitors SARS-CoV-2 Antibody Durability

By LabMedica International staff writers
Posted on 20 Oct 2021
Print article
Image: The fully automated Pylon 3-D immunochemistry system (Photo courtesy of ET HealthCare)
Image: The fully automated Pylon 3-D immunochemistry system (Photo courtesy of ET HealthCare)
Low initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers dropping to undetectable levels within months after infections have raised concerns about long-term immunity.

Seroprevalence studies have begun to show a larger extent of SARS-CoV-2 infections than initially reported because of the high prevalence of infected individuals with mild or no symptoms. However, lower SARS-CoV-2 IgG antibody levels have been reported in those with mild or no symptoms compared with those with severe COVID-19.

A team of Clinical Scientists collaborating with Weill Cornell Medicine (New York, NY, USA) developed a testing-on-a-probe “plus” panel (TOP-Plus) to include a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM, and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 5.7 weeks and 30 weeks after infection in paired samples from 80 patients with coronavirus disease 2019 (COVID-19).

Sera from individuals vaccinated for SARS-CoV-2 were also evaluated for antibody avidity. The SARS-CoV-2 TAb and SNAb assays were used to measure plasma TAb and SNAb antibodies against SARS-CoV-2. Plasma samples were assayed on the fully automated Pylon 3-D analyzer (ET HealthCare, Palo Alto, CA, USA). Bio-layer interferometry measurements (Gator Bio, Palo Alto, CA, USA) were used to compare the avidity of 12 different purified COVID-19 antibodies with the TOP-Plus avidity assay.

The investigators reported that the newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay. The imprecision of the TOP avidity assay was <10%. Although TAb and neutralization activity (by SNAb) decreased between 5.7 and 30 weeks after infection, the antibody avidity increased significantly. Antibody avidity in 10 SARS-CoV-2 vaccinated individuals (median: 28 days after vaccination) was comparable to the measured antibody avidity in infected individuals (median: 26 days after infection). No cross-reactivity was displayed in sera from patients positive for HIV, Epstein–Barr virus, or rheumatoid factor.

The authors concluded that the TOP-Plus biosensor panel is a versatile sensing platform with high precision and an ability to measure SARS-CoV-2 TAb, SNAb, and individual IgG and IgM antibody levels along with the antibody’s long-term avidity. This combination of all-in-one testing will be a valuable asset in monitoring not only patients convalescing from COVID-19, but also the status of individuals’ COVID-19 vaccination response. The study was published in the September, 2021 issue of the journal Clinical Chemistry.

Related Links:
Weill Cornell Medicine
ET HealthCare
Gator Bio


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.